Generali Investments Management Co LLC Purchases 53,194 Shares of Hims & Hers Health, Inc. $HIMS

Generali Investments Management Co LLC increased its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 2,124.4% in the third quarter, Holdings Channel.com reports. The fund owned 55,698 shares of the company’s stock after purchasing an additional 53,194 shares during the period. Generali Investments Management Co LLC’s holdings in Hims & Hers Health were worth $3,159,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Virtus Advisers LLC purchased a new stake in Hims & Hers Health during the 2nd quarter valued at $26,000. Quent Capital LLC bought a new position in shares of Hims & Hers Health during the third quarter valued at $28,000. Quaker Wealth Management LLC purchased a new stake in shares of Hims & Hers Health during the second quarter valued at $29,000. Bessemer Group Inc. boosted its position in shares of Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after buying an additional 312 shares during the last quarter. Finally, Geneos Wealth Management Inc. bought a new stake in Hims & Hers Health in the 1st quarter worth about $30,000. 63.52% of the stock is owned by institutional investors.

Analyst Ratings Changes

HIMS has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft set a $31.00 target price on shares of Hims & Hers Health and gave the company a “hold” rating in a research note on Tuesday, February 10th. Wall Street Zen cut shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Truist Financial restated a “hold” rating and issued a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a report on Tuesday. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday. Finally, Bank of America decreased their target price on shares of Hims & Hers Health from $26.00 to $21.00 and set an “underperform” rating for the company in a research note on Monday, February 9th. Two analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, Hims & Hers Health presently has an average rating of “Reduce” and an average price target of $32.27.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Management continues to emphasize growth and is pursuing a large international expansion via a planned acquisition of Eucalyptus, which could boost scale and addressable market outside the U.S. Hims And Hers Balances GLP 1 Scrutiny With Eucalyptus Expansion Plans
• Neutral Sentiment: Investor interest is elevated — unusually large options volume was reported, signaling higher speculative or hedging activity that can amplify moves in either direction. Hims & Hers Health Sees Unusually Large Options Volume (NYSE:HIMS)
• Neutral Sentiment: Comparative coverage (HIMS vs. AMWL) highlights differing telehealth strategies; useful for investors evaluating sector exposure but not an immediate catalyst. HIMS vs. AMWL: Which Telehealth Stock Is the Better Investment Now?
• Negative Sentiment: The SEC has opened an inquiry into Hims’ disclosures about compounded GLP‑1 (semaglutide) products, increasing regulatory risk and disclosure uncertainty. Hims & Hers Stock Faces Heavy Sell-Off Amid SEC Probe Into GLP-1 Disclosures
• Negative Sentiment: Novo Nordisk filed suit alleging patent infringement over compounded weight‑loss drugs; Hims withdrew its compounded semaglutide product—potential legal and liability exposure. Hims And Hers Balances GLP 1 Scrutiny With Eucalyptus Expansion Plans
• Negative Sentiment: The Law Offices of Frank R. Cruz announced an investor investigation into whether the board breached fiduciary duties related to these matters, which raises litigation risk and governance scrutiny. The Law Offices of Frank R. Cruz Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors
• Negative Sentiment: Multiple analyst actions: Citigroup cut its price target to $13.25 and BTIG downgraded HIMS to Neutral; those notes prompted downgrades and contributed to heavy intraday selling. Citigroup Lowers Hims & Hers Health (NYSE:HIMS) Price Target to $13.25 BTIG Research Downgrades Hims & Hers Health (NYSE:HIMS) to Neutral
• Negative Sentiment: Shares have hit new lows after the analyst activity and headlines; commentary also flagged potential near‑term pressure from a Super Bowl ad and changes to shipping cadence that could affect short‑term volumes. Hims & Hers Stock Stumbles – Cautions About Pressure Due To Super Bowl Ad, Change In Shipping Cadences
• Negative Sentiment: Overall coverage (TipRanks, Market commentary) highlights elevated reputation, partnership and liability risks from compounded‑drug scrutiny—factors that could weigh on sentiment until legal/regulatory clarity is reached. Regulatory Scrutiny of Compounded Drugs Puts Hims & Hers’ Growth, Partnerships, and Liability Risk in the Spotlight

Insider Transactions at Hims & Hers Health

In related news, insider Irene Becklund sold 8,411 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $308,767.81. Following the transaction, the insider directly owned 2,126 shares of the company’s stock, valued at approximately $78,045.46. The trade was a 79.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Chi sold 13,750 shares of the stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $504,762.50. Following the sale, the chief operating officer directly owned 305,161 shares of the company’s stock, valued at approximately $11,202,460.31. This trade represents a 4.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 82,963 shares of company stock valued at $2,944,621. 13.71% of the stock is owned by corporate insiders.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $15.61 on Friday. The stock has a market cap of $3.55 billion, a PE ratio of 30.61, a price-to-earnings-growth ratio of 3.38 and a beta of 2.43. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $70.43. The firm has a fifty day moving average price of $27.02 and a 200-day moving average price of $39.43. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.64.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The company had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. During the same quarter in the prior year, the firm posted $0.11 EPS. Hims & Hers Health’s quarterly revenue was up 28.4% compared to the same quarter last year. Equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health declared that its Board of Directors has authorized a share buyback program on Monday, November 17th that authorizes the company to buyback $250.00 million in shares. This buyback authorization authorizes the company to buy up to 3% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.